Neurocrine Biosciences | NBIX - 营业费用



金融业
股票价格
USD 167.24
资产
USD 5.63B
现金及等价物
USD 641.5M
销售成本
USD 61.6M
流动资产
USD 2.01B
流动负债
USD 984.6M
债务
USD 392.3M
EBIT
USD 343M
EBITDA
USD 375.3M
员工
1.8K
EPS每股收益
USD 3.29
股本和储备
USD 3.88B
销售毛利
USD 1.06B
债务利息支出
USD 300K
贷款资金
USD 169.5M
市值
USD 16.86B
净收入
USD 206.5M
营业费用
USD 779.7M
营业利润
USD 343M
普通股股本
USD 101.3M
PE价格收益
83.17
税前利润
USD 283.7M
销售收入
USD 1.12B
销售和管理费用
USD 366.3M
股票
USD 66.1M
贸易债权人
USD 754.1M
应收帐款人
USD 957.3M


营业费用 更改 日
AbbVie USD 10.52B 258M 2026-09
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
ALKERMES USD 1.86B 56.17M 2026-09
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Cytokinetics USD 214.64M 6.85M 2026-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 390.27M 10M 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
Halozyme Therapeutics USD 198M 4.66M 2026-09
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 373M 2.76M 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Pfizer USD 89B 3.81B 2026-09
Prothena USD 19.7M 5.6M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Repligen USD 185.01M 2.01M 2026-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Teva Pharmaceutical Industries USD 3.18B 733M 2026-09
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09